Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis.

Michailidou M, Giannouli V, Kotsikoris V, Papadodima O, Kontogianni G, Kostakis IK, Lougiakis N, Chatziioannou A, Kolisis FN, Marakos P, Pouli N, Loutrari H.

Eur J Med Chem. 2016 Oct 4;121:143-57. doi: 10.1016/j.ejmech.2016.05.035. Epub 2016 May 20.

PMID:
27240270
2.

Network-Based Analysis of Nutraceuticals in Human Hepatocellular Carcinomas Reveals Mechanisms of Chemopreventive Action.

Michailidou M, Melas IN, Messinis DE, Klamt S, Alexopoulos LG, Kolisis FN, Loutrari H.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):350-61. doi: 10.1002/psp4.40. Epub 2015 Jun 1.

3.

Biocatalytic synthesis and antitumor activities of novel silybin acylated derivatives with dicarboxylic acids.

Theodosiou E, Loutrari H, Stamatis H, Roussos C, Kolisis FN.

N Biotechnol. 2011 Jul;28(4):342-8. doi: 10.1016/j.nbt.2011.01.006. Epub 2011 Feb 12.

PMID:
21320648
4.

Mastic oil inhibits the metastatic phenotype of mouse lung adenocarcinoma cells.

Loutrari H, Magkouta S, Papapetropoulos A, Roussos C.

Cancers (Basel). 2011 Feb 23;3(1):789-801. doi: 10.3390/cancers3010789.

5.

The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability.

Morbidelli L, Pyriochou A, Filippi S, Vasileiadis I, Roussos C, Zhou Z, Loutrari H, Waltenberger J, Stössel A, Giannis A, Ziche M, Papapetropoulos A.

Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32. doi: 10.1152/ajpregu.00222.2009. Epub 2009 Dec 23.

6.

A transcriptomic computational analysis of mastic oil-treated Lewis lung carcinomas reveals molecular mechanisms targeting tumor cell growth and survival.

Moulos P, Papadodima O, Chatziioannou A, Loutrari H, Roussos C, Kolisis FN.

BMC Med Genomics. 2009 Dec 15;2:68. doi: 10.1186/1755-8794-2-68.

7.

Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma.

Magkouta S, Stathopoulos GT, Psallidas I, Papapetropoulos A, Kolisis FN, Roussos C, Loutrari H.

Nutr Cancer. 2009;61(5):640-8. doi: 10.1080/01635580902825647.

PMID:
19838938
8.

Zoledronic acid is effective against experimental malignant pleural effusion.

Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Zhou Z, Papiris SA, Roussos C, Kalomenidis I.

Am J Respir Crit Care Med. 2008 Jul 1;178(1):50-9. doi: 10.1164/rccm.200710-1513OC. Epub 2008 Apr 3.

PMID:
18388351
9.

Mastic oil from Pistacia lentiscus var. chia inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis.

Loutrari H, Magkouta S, Pyriochou A, Koika V, Kolisis FN, Papapetropoulos A, Roussos C.

Nutr Cancer. 2006;55(1):86-93.

PMID:
16965245
10.

Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.

Kotanidou A, Loutrari H, Papadomichelakis E, Glynos C, Magkou C, Armaganidis A, Papapetropoulos A, Roussos C, Orfanos SE.

Vascul Pharmacol. 2006 Aug;45(2):134-40. Epub 2006 Jul 25.

PMID:
16959545
11.

Perillyl alcohol is an angiogenesis inhibitor.

Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, Kolisis FN, Papapetropoulos A.

J Pharmacol Exp Ther. 2004 Nov;311(2):568-75. Epub 2004 Jun 21.

12.

Studies on the catalytic behaviour of a cholinesterase-like abzyme in an AOT microemulsion system.

Franqueville E, Stamatis H, Loutrari H, Friboulet A, Kolisis F.

J Biotechnol. 2002 Aug 7;97(2):177-82.

PMID:
12067523
14.

Diversity among abortion strains of Chlamydia psittaci demonstrated by inclusion morphology, polypeptide profiles and monoclonal antibodies.

Vretou E, Loutrari H, Mariani L, Costelidou K, Eliades P, Conidou G, Karamanou S, Mangana O, Siarkou V, Papadopoulos O.

Vet Microbiol. 1996 Aug;51(3-4):275-89.

PMID:
8870190
15.
16.

Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.

Loutrari H, Kokla A, Tzartos SJ.

Eur J Immunol. 1992 Sep;22(9):2449-52.

PMID:
1516631
17.

The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Tzartos SJ, Cung MT, Demange P, Loutrari H, Mamalaki A, Marraud M, Papadouli I, Sakarellos C, Tsikaris V.

Mol Neurobiol. 1991 Spring;5(1):1-29. Review.

PMID:
1725702
18.

The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis.

Tzartos SJ, Barkas T, Cung MT, Kordossi A, Loutrari H, Marraud M, Papadouli I, Sakarellos C, Sophianos D, Tsikaris V.

Autoimmunity. 1991;8(4):259-70. Review.

PMID:
1718457
19.

Main immunogenic region of Torpedo electroplax and human muscle acetylcholine receptor: localization and microheterogeneity revealed by the use of synthetic peptides.

Tzartos SJ, Loutrari HV, Tang F, Kokla A, Walgrave SL, Milius RP, Conti-Tronconi BM.

J Neurochem. 1990 Jan;54(1):51-61.

PMID:
1688377

Supplemental Content

Loading ...
Support Center